Abstract
Candida species are the fourth most common cause of nosocomial bloodstream infections. An increase in the frequency of infections which have become refractory to standard antifungal therapyhave been observed. Recently, the effect of different organochalcogenide compounds reducing both growth and germ tube formation by Candida albicans was demonstrated. This work studied the effect of the organochalcogenide compound (pCl-PhSe)2 on both growth and biofilm formation by Candida albicans. A decrease in C. albicans growth in the presence of crescent concentrations of (pCl- PhSe)2 was observed, in a cell density dependent manner. The inhibition of Candida growth by 10µM (pCl-PhSe)2 was ~60, 57, 47 and 24%, in cell densities of 103, 104, 105 and 106 cells/ml, respectively. The compound (pCl-PhSe)2 was able to inhibit biofilm formation by Candida albicans, when biofilm was performed using a cell density of 106 cells/ml. In addition, an increase in both ROS production (96%) and cell membrane permeability (1.107-fold) by 10 µM (pCl-PhSe)2 was observed in C. albicans.These results demonstrate that the organochalcogenide compound (pCl-PhSe)2 presents a great potential to inhibit both growth and biofilm formation by C. albicans.
Keywords: Candida albicans, biofilm, antifungal therapy, organochalcogenide compound, (pCl-PhSe)2.
Current Drug Discovery Technologies
Title:Biofilm Formation by Candida albicans is Inhibited by 4,4-Dichloro Diphenyl Diselenide (pCl-PhSe)2
Volume: 11 Issue: 3
Author(s): Isabela Bueno Rosseti, Paulo Taube Junior, Claudia Barbosa Ladeira de Campos, Joao Batista Teixeira da Rocha and Maricilia Silva Costa
Affiliation:
Keywords: Candida albicans, biofilm, antifungal therapy, organochalcogenide compound, (pCl-PhSe)2.
Abstract: Candida species are the fourth most common cause of nosocomial bloodstream infections. An increase in the frequency of infections which have become refractory to standard antifungal therapyhave been observed. Recently, the effect of different organochalcogenide compounds reducing both growth and germ tube formation by Candida albicans was demonstrated. This work studied the effect of the organochalcogenide compound (pCl-PhSe)2 on both growth and biofilm formation by Candida albicans. A decrease in C. albicans growth in the presence of crescent concentrations of (pCl- PhSe)2 was observed, in a cell density dependent manner. The inhibition of Candida growth by 10µM (pCl-PhSe)2 was ~60, 57, 47 and 24%, in cell densities of 103, 104, 105 and 106 cells/ml, respectively. The compound (pCl-PhSe)2 was able to inhibit biofilm formation by Candida albicans, when biofilm was performed using a cell density of 106 cells/ml. In addition, an increase in both ROS production (96%) and cell membrane permeability (1.107-fold) by 10 µM (pCl-PhSe)2 was observed in C. albicans.These results demonstrate that the organochalcogenide compound (pCl-PhSe)2 presents a great potential to inhibit both growth and biofilm formation by C. albicans.
Export Options
About this article
Cite this article as:
Rosseti Bueno Isabela, Junior Taube Paulo, Campos Barbosa Ladeira de Claudia, Rocha Batista Teixeira da Joao and Costa Silva Maricilia, Biofilm Formation by Candida albicans is Inhibited by 4,4-Dichloro Diphenyl Diselenide (pCl-PhSe)2, Current Drug Discovery Technologies 2014; 11 (3) . https://dx.doi.org/10.2174/1570163811666140924121758
DOI https://dx.doi.org/10.2174/1570163811666140924121758 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Techniques to Investigate Neuronal Mitochondrial Function and its Pharmacological Modulation
Current Drug Targets Clinical and Genetic Aspects of the Joubert Syndrome: a Disorder Characterised by Cerebellar Vermian Hypoplasia and Accompanying Brainstem Malformations
Current Genomics A New Aspect of the TrkB Signaling Pathway in Neural Plasticity
Current Neuropharmacology Imaging of Wallerian Degeneration in the Brain
Current Medical Imaging Pathways of Acetylcholine Synthesis, Transport and Release as Targets for Treatment of Adult-Onset Cognitive Dysfunction
Current Medicinal Chemistry Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Cell Transplantation: A Future Therapy for Narcolepsy?
CNS & Neurological Disorders - Drug Targets Genetic Control of Sister Chromatid Recombination: The Role of Radiation Repair (RAD) Genes
Current Genomics Astrocytes: Targets for Neuroprotection in Stroke
Central Nervous System Agents in Medicinal Chemistry PET Radioligands for the Vesicular Acetylcholine Transporter (VAChT)
Current Topics in Medicinal Chemistry An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Cyclin-Dependent Kinase Inhibitors: Cancer Killers to Neuronal Guardians
Current Medicinal Chemistry Inhibitors of Cyclin-Dependent Kinases: Potential Drugs for the Treatment of Neurodegenerative Disorders?
Current Medicinal Chemistry - Central Nervous System Agents Advanced QSAR Methods Evaluated Polycyclic Aromatic Compounds Duality as Drugs and Inductors in Psychiatric Disorders
Current Organic Chemistry Pharmacology of Cell Adhesion Molecules of the Nervous System
Current Neuropharmacology Delivering RNA Interference to the Mammalian Brain
Current Gene Therapy Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued)